Clobex Shortage: What Providers and Prescribers Need to Know in 2026

For dermatologists, PCPs, nurse practitioners, and other prescribers managing patients on Clobex (clobetasol propionate 0.05%), supply inconsistencies in 2026 present real clinical challenges. Patients who rely on this Class I super-potent topical corticosteroid for moderate to severe psoriasis or other severe dermatoses may experience treatment gaps — with potential for significant disease flares. This clinical briefing covers the current supply situation, therapeutic implications, suitable alternatives, and tools to support your patients.

Current Supply Status of Clobex in 2026

Clobex is not universally declared under an FDA shortage, but real-world availability at the pharmacy level is inconsistent. The ointment formulation of clobetasol propionate has been most affected, with manufacturer discontinuations reducing overall supply. Brand-name Clobex shampoo, lotion, and spray show variable availability depending on region and pharmacy type. Generic clobetasol propionate cream and solution are generally the most consistently stocked alternatives.

Importantly, availability varies significantly between pharmacy chains, independent pharmacies, and specialty pharmacy channels. Patients who have been told "it's not available" at one location may be able to fill their prescription at another. This creates a burden on both patients and providers when it comes to managing care effectively.

Clinical Implications of Supply Disruptions

When patients cannot access Clobex, several clinical concerns arise:

Disease flares: Untreated severe psoriasis, eczema, or other corticosteroid-responsive dermatoses can worsen rapidly. For patients in the middle of an induction phase with Clobex, interruption can be clinically significant.

Rebound phenomenon: Abrupt discontinuation of a super-potent corticosteroid following extended use may cause rebound dermatitis that can be more severe than the original condition.

HPA axis considerations: Clobetasol propionate is highly potent; clinical trials documented HPA axis suppression in 5 of 12 adolescent subjects after just 4 weeks of shampoo use. Patients on extended clobetasol therapy who must abruptly stop due to a shortage should be monitored for adrenal insufficiency symptoms.

Patient adherence: Patients who cannot fill their prescription may self-treat inappropriately, use expired medication, or simply abandon treatment — all of which carry clinical risk.

Recommended Therapeutic Alternatives

When clobetasol propionate is unavailable, the following alternatives should be considered, in order of clinical proximity:

Class I Alternatives (Super-Potent)

Halobetasol propionate 0.05% (Ultravate, Bryhali): Most direct substitute. Double-blind trials show 89-93% comparable success rates. Available in cream, ointment, and lotion (Bryhali). Generic halobetasol propionate is widely available.

Augmented betamethasone dipropionate 0.05% (Diprolene): Class I gel or ointment. Limited to 2 weeks of use. Note: non-augmented betamethasone dipropionate is only Class II — confirm formulation.

Class II Alternatives (High-Potency)

Fluocinonide 0.05-0.1% (Vanos): Well-established, widely available in generic form. Appropriate for moderate-to-severe disease where Class I steroid is preferred but unavailable.

Desoximetasone 0.25% (Topicort): 68% improvement vs. 23% vehicle in 3-week eczema studies. Available in cream, ointment, and gel.

Non-Steroidal Options for Long-Term Management

Calcipotriene (Dovonex) or calcipotriene/betamethasone combination (Taclonex): Vitamin D analog for psoriasis. Combination products improve efficacy over either agent alone. Useful for scalp and body psoriasis.

Roflumilast (Zoryve): FDA-approved nonsteroidal topical PDE4 inhibitor for plaque psoriasis. Steroid-sparing alternative for patients on long-term therapy.

Prescribing Considerations During a Shortage

Write "brand medically necessary" only when clinically justified. In most cases, generic clobetasol propionate is therapeutically equivalent and more widely available.

Specify formulation flexibility. If you prescribe clobetasol shampoo but write flexibility for cream or lotion if shampoo is unavailable, your patients have better access options.

Prepare an alternative prescription. Consider having a backup prescription for halobetasol propionate ready to send to the pharmacy if clobetasol cannot be found.

Communicate proactively with patients. Patients who know about potential shortages can plan ahead — refilling earlier, checking multiple pharmacies, and avoiding treatment gaps.

Tools to Help Your Patients Find Clobex

medfinder for Providers at medfinder.com/providers gives your practice tools to help patients locate Clobex at pharmacies near them. You can also review our companion guide: How to Help Your Patients Find Clobex in Stock.